Current Report Filing (8-k)
08 June 2019 - 7:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 7, 2019
ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
000-52446
|
|
74-2963609
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
275 Madison Avenue, 7th Floor
New York, NY
|
|
10016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(646) 677-3870
N/A
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of exchange on which registered
|
Common stock, par value $0.001
|
|
ATNM
|
|
NYSE American
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As of March 31, 2019, Actinium Pharmaceuticals,
Inc.’s (the “Company”) stockholders’ equity was below $6 million, the minimum required for continued listing
on the NYSE American pursuant to Section 1003(a)(iii) of the NYSE American Company Guide since the Company has incurred losses
in its five most recent fiscal years. However, subsequent to March 31, 2019 and as of the date of filing of the Form 10-Q for the
quarterly period ended March 31, 2019 that was filed with the Securities and Exchange Commission on May 10, 2019, the Company’s
stockholders’ equity was above $6 million as a result of the closing of a public offering in April 2019. The Company sold
42.9 million shares of common stock at an offering price of $0.385 per share and warrants to purchase up to 42.9 million shares
of common stock at an exercise price of $0.50 per share and with a term of 5 years, resulting in gross proceeds of $16.5 million
and net proceeds of $15.1 million after deducting underwriting and other offering expenses. The financing added $15.1 million to
stockholders’ equity.
Dated: June 7, 2019
|
ACTINIUM PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Sandesh Seth
|
|
Name:
|
Sandesh Seth
|
|
Title:
|
CEO & Chairman
|
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Apr 2024 to May 2024
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From May 2023 to May 2024